Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript - Thomson StreetEvents

Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript

Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript - Thomson StreetEvents
Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript
Published Jun 30, 2022
13 pages (9732 words) — Published Jun 30, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of LXRX.OQ conference call or presentation 30-Jun-22 12:00pm GMT

  
Brief Excerpt:

...Operator Good morning, ladies and gentlemen, and welcome to the Lexicon Pharmaceuticals, Inc. Top Line Results for LX9211 Conference Call. (Operator Instructions) This call is being recorded today, Thursday, June 30, 2022. And I would now like to turn the conference over to Mr. Michael O'Kelly. Please go ahead, sir. Unidentified Company Representative Thank you, Michelle. Good morning, and welcome to Lexicon Pharmaceuticals conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; and Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer. Yesterday afternoon, Lexicon issued a press release reporting positive top line results from our RELIEF-DPN-1 Phase II proof-of-concept study of LX9211 in painful diabetic neuropathy, which is available on our website at www.lexpharma.com. A webcast of this call, along with the slide presentation is available on our website. During this call,...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Lexicon Pharmaceuticals Inc
Ticker
LXRX.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Just a couple of kind of clarifiers for me. I appreciate you providing the baseline average daily pain scores across the overall study population. Can you provide that per each arm?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : And I think you said more patients were on background pain medicine in placebo arms and the active arms in addition to using some more Tylenol as the study progressed. Can you quantify that imbalance? Did you say it was statistically significant?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got you. I also have a couple of questions on tolerability in light of what sounds like higher dropouts on the experimental arm despite what looks like some signal of improved pain scores. So I'm curious, what were the rates of dizziness and nausea by arm?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. And I'm curious if you guys have taken a look at how many side effects were early and maybe associated with the Cmax at that loading dose relative to the lower ongoing dose levels?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Got it. And just to clarify on what you guys see as the next step (inaudible)? I understand that partner would likely be involved in kind of making some decisions here as well. Do you guys think more of Phase IIb work is in order to confirm the best dose? Or do you think this product could be poised to go right into some pivotal trials?

Table Of Contents

Lexicon Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2023-01-12 – US$ 54.00 – Edited Transcript of LXRX.OQ presentation 12-Jan-23 8:00pm GMT

Lexicon Pharmaceuticals Inc RELIEF-PHN-1 Call Transcript – 2022-12-21 – US$ 54.00 – Edited Transcript of LXRX.OQ conference call or presentation 21-Dec-22 10:00pm GMT

Lexicon Pharmaceuticals Inc LX9211 Call Transcript – 2022-11-14 – US$ 54.00 – Edited Transcript of LXRX.OQ conference call or presentation 14-Nov-22 10:00pm GMT

Lexicon Pharmaceuticals Inc Q3 2022 Earnings Call Transcript – 2022-11-09 – US$ 54.00 – Edited Transcript of LXRX.OQ earnings conference call or presentation 9-Nov-22 10:00pm GMT

Lexicon Pharmaceuticals Inc Q2 2022 Earnings Call Transcript – 2022-08-02 – US$ 54.00 – Edited Transcript of LXRX.OQ earnings conference call or presentation 2-Aug-22 9:00pm GMT

Lexicon Pharmaceuticals Inc Q1 2022 Earnings Call Transcript – 2022-05-05 – US$ 54.00 – Edited Transcript of LXRX.OQ earnings conference call or presentation 5-May-22 12:00pm GMT

Lexicon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript – 2022-04-12 – US$ 54.00 – Edited Transcript of LXRX.OQ presentation 12-Apr-22 12:45pm GMT

Lexicon Pharmaceuticals Inc Q4 2021 Earnings Call Transcript – 2022-02-28 – US$ 54.00 – Edited Transcript of LXRX.OQ earnings conference call or presentation 28-Feb-22 1:00pm GMT

Lexicon Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-13 – US$ 54.00 – Edited Transcript of LXRX.OQ presentation 13-Jan-22 3:30pm GMT

Lexicon Pharmaceuticals Inc Q3 2021 Earnings Call Transcript – 2021-11-03 – US$ 54.00 – Edited Transcript of LXRX.OQ earnings conference call or presentation 3-Nov-21 9:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript" Jun 30, 2022. Alacra Store. Apr 24, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Lexicon-Pharmaceuticals-Inc-RELIEF-DPN-1-Call-T15255787>
  
APA:
Thomson StreetEvents. (2022). Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript Jun 30, 2022. New York, NY: Alacra Store. Retrieved Apr 24, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Lexicon-Pharmaceuticals-Inc-RELIEF-DPN-1-Call-T15255787>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.